These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30287855)

  • 1. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
    Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
    Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
    Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
    Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
    Illés Á; Pinczés LI; Egyed M
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
    Wagner SM; Melchardt T; Greil R
    Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
    Qin A; Wu D; Li Y; Zhang J; Wang W; Shen W; Liao J; Lin S; Chang C; Chen H; Cui J; Su X
    Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.
    Shimoda K; Qin A; Komatsu N; Kirito K
    Int J Hematol; 2024 Aug; 120(2):151-156. PubMed ID: 38951434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
    Barbui T; Vannucchi AM; De Stefano V; Masciulli A; Carobbio A; Ferrari A; Ghirardi A; Rossi E; Ciceri F; Bonifacio M; Iurlo A; Palandri F; Benevolo G; Pane F; Ricco A; Carli G; Caramella M; Rapezzi D; Musolino C; Siragusa S; Rumi E; Patriarca A; Cascavilla N; Mora B; Cacciola E; Mannarelli C; Loscocco GG; Guglielmelli P; Betti S; Lunghi F; Scaffidi L; Bucelli C; Vianelli N; Bellini M; Finazzi MC; Tognoni G; Rambaldi A
    Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
    Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
    Edahiro Y; Ohishi K; Gotoh A; Takenaka K; Shibayama H; Shimizu T; Usuki K; Shimoda K; Ito M; VanWart SA; Zagrijtschuk O; Qin A; Kawase H; Miyachi N; Sato T; Komatsu N; Kirito K
    Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
    Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
    Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.
    Gerds AT; Castro C; Snopek F; Flynn MM; Ellis AG; Manning M; Urbanski R
    J Comp Eff Res; 2023 Sep; 12(9):e230066. PubMed ID: 37531245
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.
    Qin A
    Clin Ther; 2024 May; 46(5):439-440. PubMed ID: 38697872
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.
    Zhang ZR; Duan YC
    Asian Pac J Cancer Prev; 2014; 15(4):1681-4. PubMed ID: 24641389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
    Gisslinger H; Zagrijtschuk O; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Kralovics R; Gisslinger B; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Schalling M; Them NC; Kadlecova P; Klade C; Greil R
    Blood; 2015 Oct; 126(15):1762-9. PubMed ID: 26261238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.
    Lu M; Wang J; Li Y; Berenzon D; Wang X; Mascarenhas J; Xu M; Hoffman R
    Blood; 2010 Nov; 116(20):4284-7. PubMed ID: 20625010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel germline JAK2
    Song J; Lanikova L; Kim SJ; Papadopoulos N; Meznarich J; Constantinescu SN; Parsegov B; Prchal JF; Prchal JT
    Am J Hematol; 2024 Jul; 99(7):1220-1229. PubMed ID: 38629639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
    Kiladjian JJ; Cassinat B; Turlure P; Cambier N; Roussel M; Bellucci S; Menot ML; Massonnet G; Dutel JL; Ghomari K; Rousselot P; Grange MJ; Chait Y; Vainchenker W; Parquet N; Abdelkader-Aljassem L; Bernard JF; Rain JD; Chevret S; Chomienne C; Fenaux P
    Blood; 2006 Sep; 108(6):2037-40. PubMed ID: 16709929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.
    Lu M; Wang X; Li Y; Tripodi J; Mosoyan G; Mascarenhas J; Kremyanskaya M; Najfeld V; Hoffman R
    Blood; 2012 Oct; 120(15):3098-105. PubMed ID: 22872685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.